You are here: Industry Insights > HCM

News List

AHA News: Genetic Problem Led to a Heart Transplant at 24. Her New Heart Has a Genetic Problem, Too. drugs
July 15, 2021
At 13, Leilani Graham was running on the treadmill in her garage when she suddenly collapsed. Her mother, who was supposed to be gone, heard a bizarre moaning sound coming from the garage and rushed to find her daughter unconscious.
Human Capital Management (HCM) Solutions Market with COVID-19 Impact and Analysis | Technavio prnewswire
June 30, 2021
Set to grow by USD 11.13 billion during 2020-2024, Technavio's latest market research report estimates the human capital management (HCM) solutions market to register a CAGR of about 10%.
BMS acquires biopharma firm MyoKardia for $13.1bn pharmaceutical-technology
November 19, 2020
Bristol Myers Squibb (BMS) has completed its acquisition of clinical-stage biopharma firm MyoKardia in an all-cash transaction for $13.1bn.
BMS to acquire biopharma firm MyoKardia for $13.1bn pharmaceutical-technology
October 10, 2020
Bristol Myers Squibb (BMS) has signed a definitive merger agreement to acquire clinical-stage biopharma firm MyoKardia, in a cash-based transaction valued at $13.1bn.
MyoKardia Receives Breakthrough Therapy Designation for Mavacamten americanpharmaceuticalreview
July 30, 2020
MyoKardia announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy.
Obstructive Hypertrophic Cardiomyopathy Study from MyoKardia Meets Primary, Secondary Endpoints americanpharmaceuticalreview
May 15, 2020
MyoKardia announced positive topline data from the company’s Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM).